9ZT Stock Chart & Stats
€194.40
--
Market closed
€194.40
--
Day’s Range― - ―
52-Week Range€194.40 - €194.40
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€5.44M
Enterprise Value€1.21M
Total Cash (Recent Filing)€710.69K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.00
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,791,525
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.19
Price to Sales (P/S)0.00
P/FCF Ratio-0.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Alzamend Neuro News
9ZT FAQ
What was Alzamend Neuro, Inc.’s price range in the past 12 months?
Alzamend Neuro, Inc. lowest stock price was €194.40 and its highest was €194.40 in the past 12 months.
What is Alzamend Neuro, Inc.’s market cap?
Alzamend Neuro, Inc.’s market cap is €5.44M.
When is Alzamend Neuro, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Alzamend Neuro, Inc.’s earnings last quarter?
Currently, no data Available
Is Alzamend Neuro, Inc. overvalued?
According to Wall Street analysts Alzamend Neuro, Inc.’s price is currently Overvalued.
Does Alzamend Neuro, Inc. pay dividends?
Alzamend Neuro, Inc. does not currently pay dividends.
What is Alzamend Neuro, Inc.’s EPS estimate?
Alzamend Neuro, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alzamend Neuro, Inc. have?
Alzamend Neuro, Inc. has 4,791,525 shares outstanding.
What happened to Alzamend Neuro, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Alzamend Neuro, Inc.?
Currently, no hedge funds are holding shares in DE:9ZT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alzamend Neuro, Inc.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Galmed Pharmaceuticals
―
Quoin Pharmaceuticals
―
Adial Pharmaceuticals
―
Silo Pharma
―
Calidi Biotherapeutics
―